LZM009 to Treat Patients With Advanced Solid Tumors

NCT03286296 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

BIOLOGICAL: LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection

Sponsor

Livzon Pharmaceutical Group Inc.